D. Boral Capital Initiates Biomea Fusion(BMEA.US) With Buy Rating, Announces Target Price $16

Futu NewsJan 13 23:33 · Ratings

Express News | Biomea Fusion: Based on Most Recent Trial Results, Strategic Focus for Icovamenib Will Be in Metabolic Disorders

BreakingsJan 13 22:01

Biomea Fusion to Become a Diabetes & Obesity Medicines Company

GlobeNewswireJan 13 22:00

Biomea Fusion Is Maintained at Buy by D. Boral Capital

Dow JonesJan 10 21:06 · Ratings

Biomea Fusion Price Target Maintained With a $128.00/Share by D. Boral Capital

Dow JonesJan 10 21:06 · Ratings

Barclays Maintains Biomea Fusion(BMEA.US) With Hold Rating, Maintains Target Price $11

Futu NewsJan 9 17:34 · Ratings